MedPath

Cangrelor in Patients With Acute Myocardial Infarction Undergoing PCI After CPR, Ventilated or Cardiogenic Shock

Completed
Conditions
Acute Myocardial Infarction
Registration Number
NCT04611607
Lead Sponsor
IHF GmbH - Institut für Herzinfarktforschung
Brief Summary

This registry will provide information about the efficacy and safety of cangrelor in a very high-risk group of patients with acute myocardial infarction undergoing PCI. It will not only include patients with cardiogenic shock, but a variety of patients not able to swallow tablets, such as those after CPR and/or with invasive or non-invasive ventilation. Therefore it will provide information about the use of cangrelor beyond the current knowledge.

Detailed Description

This registry is a non-interventional, multicentre, retrospective cohort study in patients with acute myocardial infarction undergoing PCI after CRP, ventilated and/or with cardiogenic shock.

The study is purely observational; data will be documented retrospectively based on available medical records. No additional data will be collected, no study-related treatment will be initiated.

About 10 - 20 high-volume PCI clinics in Germany treating patients with myocardial infarction are eligible for participation. Participating sites will be given a maximum of 6 months for retrospectively documenting eligible patients.

Eligible are all patients with acute myocardial infarction (STEMI, NSTEMI) who underwent PCI after CRP, ventilated and/or with cardiogenic shock and were treated with cangrelor during index procedure. It is planned to enrol about 400 patients in total. Patient characteristics, procedural details and clinical events occurring during the period between index MI and discharge or death (whichever came first) will be documented based on the relevant existing medical charts of the patients.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
303
Inclusion Criteria
  • Age ≥18 years
  • Acute Myocardial infarction (NSTEMI or STEMI)
  • PCI with stent implantation
  • Treatment with cangrelor during index procedure
  • At least one of the following criteria:
  • CPR prior to PCI
  • Cardiogenic shock
  • Heart failure with the need for mechanical or non-invasive ventila-tion
Exclusion Criteria

No explicit medical exclusion criteria are stated to avoid selection bias.

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Definite stent thrombosisfrom procedure for index MI up to 48 hours

Rate of stent thromboses

Recurrent myocardial infarctionfrom procedure for index MI up to 48 hours

Rate of recurrent myocardial infarction according to the universal definition of MI

Secondary Outcome Measures
NameTimeMethod
Recurrent myocardial infarctionfrom procedure for index MI until discharge from hospital or intrahosptal death, whichever came first; up to 30 days

Rate of recurrent myocardial infarction according to the universal definition of MI

Mortalityfrom procedure for index MI until discharge from hospital; up to 30 days

Rate of death

Definite stent thrombosisfrom procedure for index MI until discharge from hospital or intrahosptal death, whichever came first; up to 30 days

Rate of stent thromboses

Bleeding complicationsfrom procedure for index MI until discharge from hospital or intrahosptal death, whichever came first; up to 30 days

Rate of bleeding complication according to BARC definition

Trial Locations

Locations (10)

Universitätsklinikum Graz

🇦🇹

Graz, Austria

Fürst-Stirum Klinikum Bruchsal

🇩🇪

Bruchsal, Germany

Klinik Ottakring

🇦🇹

Wien, Austria

Universitätsklinikum Freiburg

🇩🇪

Freiburg, Germany

Klinikum Leverkusen

🇩🇪

Leverkusen, Germany

Klinikum Ludwigshafen

🇩🇪

Ludwigshafen, Germany

Hegau-Bodensee Klinikum Singen

🇩🇪

Singen, Germany

Universitätsklinikum Mannheim

🇩🇪

Mannheim, Germany

Krankenhaus Maria-Hilf

🇩🇪

Stadtlohn, Germany

Universitätsklinikum Tübingen

🇩🇪

Tübingen, Germany

© Copyright 2025. All Rights Reserved by MedPath